Finch Therapeutics Group, Inc.

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- T ATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB"). The SAB will advise the Company and its leadership team on strategic matters, research and development initiatives, and other areas where their expertise is beneficial to the growth of TATAA's services. The inaugural members of the SAB include Dr. Binodh DeSilva, Dr. Kaia Sartori, Dr. Lydia Michaut, Dr. Matthias Machacek, and Dr. Zain Kassam. "We are excited to have such a distinguished group of experts on our Scientific Advisory Board. Their collective expertise will be invaluable as we expand our services in personalized medicine to improve lives. The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals." said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA. Binodh DeSilva Dr. DeSilva is a seasoned senior healthcare industry executive with over 25 years of experience. She brings specialized expertise across the entire drug discovery and development continuum and has held leadership roles at Ultragenyx, Bristol-Myers Squibb, and Amgen. Dr. DeSilva holds a PhD in Bioanalytical Chemistry. Dr. DeSilva formerly served as the president of the American Association for Pharmaceutical Sciences and has authored multiple industry guidelines for bioanalysis. Kaia Sartori Dr. Sartori brings decades of experience in regulated bioanalysis to TATAA, having served in various leadership roles including at Amador Bioscience (VP Bioanalysis and Biomarkers), AstraZeneca (Director of Integrated Bioanalysis), and PPD (Group Leader). Dr. Sartori holds a PhD in Medicinal Chemistry. Throughout her career, Dr. Sartori has been the bioanalytical lead for global submission dossiers, including eight new drug approvals in 2021 and 2022. Lydia Michaut Dr. Michaut is a distinguished molecular immunology expert in the development and regulatory approval of biologics and gene therapy drugs. Her expertise spans decades encompassing academic, global pharma, CROs, and consultancy. She currently holds a pivotal position at Novartis as Director Scientific Governance. Dr. Michaut earned a PhD in Molecular Biology and Innate Immunity, during which she was directly involved in the work that merited the 2011 Nobel Prize in Physiology and Medicine for Dr. Jules Hoffmann. Dr. Michaut has supported the full drug development continuum across multiple therapeutic areas to enable the successful approval of biologics and gene therapies. Matthias Machacek Dr. Machacek is an expert in Model-Based Drug Development of biotherapeutics and is the Founder and Managing Director of LYO-X AG, a strategic consulting and PK/PD modelling services provider based in Switzerland. Prior to founding LYO-X, he served as Medical Engineering Group Head at Novartis. Dr. Machacek holds a PhD in Fluid Dynamics. Dr. Machacek has helped numerous biopharma companies make critical decisions to advance their therapies, both through LYO-X and local accelerators. Zain Kassam Dr. Kassam is an entrepreneur, investor, senior biotechnology executive, and physician-scientist. He has expertise at the intersection of medicine, biological engineering, and computer science. Dr. Kassam is the co-founder and former Chief Medical Officer of Finch Therapeutics Group, a Nasdaq-listed precision microbiome biotechnology company, and OpenBiome, a national supplier of donor-derived treatments. He has led Phase I-III clinical trials with academic collaborators across multiple therapeutic areas. Dr. Kassam holds an MPH degree from Harvard University in Quantitative Methods with a focus on clinical trials and completed post-doctoral training at MIT in biological engineering/AI. He was awarded an MD from Western University and completed his Internal Medicine and Gastroenterology training at McMaster University. TATAA has been providing molecular analysis services for over 20 years and has established itself as a leader in the field. The SAB's extensive experience in bioanalysis and next-generation biotherapeutics makes them an invaluable asset to TATAA. Contact for more info: Martin Cooke, TATAA Biocenter, Marketing & Comms Specialist. Email: [email protected] The following files are available for download: SOURCE Tataa Biocenter

MUNICH--(BUSINESS WIRE)-- mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO). Dr. Weidenmaier will contribute nearly 20 years of experience in the microbiome and infectious diseases fields and lead the company’s discovery and development efforts as they establish a pipeline of complex microbiome ecosystems product candidates. Over the course of his career, Dr. Weidenmaier has successfully developed and led R&D efforts for next-generation microbiome products. The appointment will strategically expand the mbiomics’ leadership team on its mission to harness the full potential of the microbiome to restore health and overcome disease. "Christopher's proven track record in the microbiome field, ranging from product conceptualization to clinical development, will be instrumental in further advancing our R&D strategy and execution," said Laura Figulla, PhD, CEO and Co-founder of mbiomics. “His insights and deep expertise will be a crucial asset enabling us to build an industry-leading pipeline of rationally selected microbial communities unlocking the immunological and metabolic potential of the gut microbiome.” "We as an industry have only scratched the surface of microbiome-based therapy’s potential. mbiomics is aiming to change this by advancing a precise and highly curated approach that combines cutting-edge profiling technologies and patient data insights to address the current bottlenecks in the development of effective, and safe microbiome-based therapeutics. I appreciate the opportunity to join this knowledgeable team and look forward to working together to change the treatment paradigm of severe and chronic diseases," added Christopher Weidenmaier, PhD, CSO of mbiomics. Dr. Weidenmaier previously served as the Director of Research and Head of Host Cell Biology/Immunology at Finch Therapeutics in Somerville, Massachusetts where he led the preclinical discovery and development efforts for microbiome therapeutics before continuing as a Scientific Advisory Board Member. Previously, he worked as Principal Investigator at the University of Tübingen where he authored over 40 scientific publications and received the prestigious research award (Foerderpreis) of the German Society for Microbiology and Hygiene (DGHM). He also held postdoctoral positions at the University of Tübingen and the Division of Infectious Diseases of the Brigham and Women's Hospital and Harvard Medical School in Boston. Dr. Weidenmaier holds a PhD in Microbiology from the University of Tübingen, Germany. About mbiomics mbiomics designs and develops complex microbiome-based therapeutics to change the treatment paradigm of severe and chronic diseases. Bringing together proprietary precision analytics and patient insights, we are building a pipeline of rationally selected microbial communities to achieve indication-specific activity and address patient heterogeneity. Our goal is to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease. View source version on businesswire.com: Contacts mbiomics Laura Figulla, PhD, CEO and Co-founder Email: info@mbiomics.com mbiomics media inquiries Trophic Communications Stephanie May, PhD Email: mbiomics@trophic.eu Phone: +49 171 185 56 82 Source: mbiomics View this news release online at:

NEW YORK, Aug. 2, 2023 /PRNewswire/ -- The human microbiome therapeutics market size is estimated to increase by USD 732.95 million from 2022 to 2027, at a CAGR of 30.11%, according to a recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region. Discover some insights on market size before buying the full report -Request a sample report Human Microbiome Therapeutics Market 2023-2027 – Vendor Scope Continue Reading Technavio has announced its latest market research report titled Global Human Microbiome Therapeutics Market The human microbiome therapeutics market report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 companies listed below - 4D Pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc. Download a Sample Rep ort Chart & Data Table on 5-Year Historic (2017-2021) Market Size, Comparative Analysis of Segments, and Y-O-Y Growth of Human microbiome therapeutics market Human Microbiome Therapeutics Market 2023-2027: Segmentation The market is segmented by product (probiotics, prebiotics, medical foods, and prescription drugs), application (gastrointestinal disorders, infectious diseases, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)) The market share of the probiotics segment is estimated to witness significant growth during the forecast period. Probiotics are living microbes that, when given in sufficient quantities, boost the host's health. Probiotics are bacteria and yeast that support a balanced microbial environment in human intestines. They are generally found in yogurt and other fermented foods. Additionally, they improve the immune system and shield lipids and proteins from oxidative damage. Hence, these factors are expected to drive segment growth during the forecast period. North America is estimated to contribute 41% to the growth of the global market during the forecast period. However, the region is expected to be slower than Europe and Asia. The market in the region is driven by factors such as significant investments in R & D for the development of novel therapeutic procedures and a high prevalence of gastrointestinal, metabolic, and immunological illnesses. Hence, these factors are expected to drive segment growth during the forecast period. To procure the data - Buy the report! Human Microbiome Therapeutics Market 2023-2027 – Market Dynamics Key Driver The growing prevalence of chronic diseases is a key factor driving market growth. These diseases also lead to the development of other serious diseases which include diabetes, hypertension, and obesity. Hypertension can also be caused by improper lifestyle choices and genetic factors. High blood pressure usually causes no symptoms. In addition, studies have shown that obese middle-aged men have a 50 to 60% higher risk of heart failure than nonobese middle-aged men. Hence, these factors are expected to drive market growth during the forecast period. Major Trends The increase in industry-academia collaboration for the development of novel therapeutics is a major trend in the market. To support the R&D of novel medicines for the treatment of diabetes, the major companies in the global pharmaceutical drugs industry are increasingly extending their assistance to academic institutions. Collaborations between businesses and academic institutions make it possible to combine the marketing knowledge of pharmaceutical companies with the scientific competence of academic organizations. Hence, this trend is expected to drive market growth during the forecast period. Significant Challenges The indiscriminate use of antibiotics is a significant challenge restricting market growth. In primary care, where viruses typically cause infections, overprescribing of antibiotics is a problem. The already overcrowded healthcare system incurs additional costs because of antibiotic resistance because it reduces both the number of medications that may be used for treatment and the long-term efficacy of the currently available drugs. But indiscriminate antibiotic use harms our body's natural flora and interferes with the effectiveness of microbial medicinal medicines. Hence, the above-mentioned factors are expected to restrict market growth during the forecast period. For Insights on the market dynamics & segmentations VIEW PDF SAMPLE! What are the key data covered in this Human Microbiome Therapeutics Market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the human microbiome therapeutics market between 2023 and 2027 Precise estimation of the size of the human microbiome therapeutics market and its contribution to the market with a focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the human microbiome therapeutics market across North America, Europe, Asia, and Rest of the World (ROW) A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of human microbiome therapeutics market companies. Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports The vertigo drugs market is estimated to grow by USD 551.42 million at a CAGR of 5.58% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by type (vertigo, and central vertigo), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Integration of digital health solutions in vertigo is a major trend in the market. The specialty pharmaceuticals market is estimated to grow by USD 331.12 billion at a CAGR of 12.59% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by application (oncology, multiple sclerosis, inflammatory conditions, infectious diseases, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The increasing demand for R&D due to government healthcare expenditure is a key factor driving market growth during the forecast period. Table of Contents 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by Application Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of companies included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global human microbiome therapeutics market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on global human microbiome therapeutics market 2017 - 2021 ($ million) 4.2 Product Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million) 4.3 Application Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Probiotics - Market size and forecast 2022-2027 Exhibit 34: Chart on Probiotics - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Probiotics - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Probiotics - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Probiotics - Year-over-year growth 2022-2027 (%) 6.4 Prebiotics - Market size and forecast 2022-2027 Exhibit 38: Chart on Prebiotics - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Prebiotics - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Prebiotics - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Prebiotics - Year-over-year growth 2022-2027 (%) 6.5 Medical foods - Market size and forecast 2022-2027 Exhibit 42: Chart on Medical foods - Market size and forecast 2022-2027 ($ million) Exhibit 43: Data Table on Medical foods - Market size and forecast 2022-2027 ($ million) Exhibit 44: Chart on Medical foods - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Medical foods - Year-over-year growth 2022-2027 (%) 6.6 Prescription drugs - Market size and forecast 2022-2027 Exhibit 46: Chart on Prescription drugs - Market size and forecast 2022-2027 ($ million) Exhibit 47: Data Table on Prescription drugs - Market size and forecast 2022-2027 ($ million) Exhibit 48: Chart on Prescription drugs - Year-over-year growth 2022-2027 (%) Exhibit 49: Data Table on Prescription drugs - Year-over-year growth 2022-2027 (%) 6.7 Market opportunity by Product Exhibit 50: Market opportunity by Product ($ million) Exhibit 51: Data Table on Market opportunity by Product ($ million) 7 Market Segmentation by Application 7.1 Market segments Exhibit 52: Chart on Application - Market share 2022-2027 (%) Exhibit 53: Data Table on Application - Market share 2022-2027 (%) 7.2 Comparison by Application Exhibit 54: Chart on Comparison by Application Exhibit 55: Data Table on Comparison by Application 7.3 Gastrointestinal disorders - Market size and forecast 2022-2027 Exhibit 56: Chart on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million) Exhibit 57: Data Table on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million) Exhibit 58: Chart on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%) 7.4 Infectious diseases - Market size and forecast 2022-2027 Exhibit 60: Chart on Infectious diseases - Market size and forecast 2022-2027 ($ million) Exhibit 61: Data Table on Infectious diseases - Market size and forecast 2022-2027 ($ million) Exhibit 62: Chart on Infectious diseases - Year-over-year growth 2022-2027 (%) Exhibit 63: Data Table on Infectious diseases - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by Application Exhibit 68: Market opportunity by Application ($ million) Exhibit 69: Data Table on Market opportunity by Application ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 71: Chart on Market share by geography 2022-2027 (%) Exhibit 72: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 73: Chart on Geographic comparison Exhibit 74: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 Germany - Market size and forecast 2022-2027 Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.9 France - Market size and forecast 2022-2027 Exhibit 99: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 100: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 101: Chart on France - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on France - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 111: Market opportunity by geography ($ million) Exhibit 112: Data Tables on Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 113: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 114: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 115: Overview on factors of disruption 11.4 Industry risks Exhibit 116: Impact of key risks on business 12 Vendor Analysis 12.1 Companies covered Exhibit 117: Companiescovered 12.2 Market positioning of companies Exhibit 118: Matrix on vendor position and classification 12.3 4D pharma Plc Exhibit 119: 4D pharma Plc - Overview Exhibit 120: 4D pharma Plc - Product / Service Exhibit 121: 4D pharma Plc - Key offerings 12.4 BiomX Inc. Exhibit 122: BiomX Inc. - Overview Exhibit 123: BiomX Inc. - Product / Service Exhibit 124: BiomX Inc. - Key offerings 12.5 Eligo Bioscience Exhibit 125: Eligo Bioscience - Overview Exhibit 126: Eligo Bioscience - Product / Service Exhibit 127: Eligo Bioscience - Key offerings 12.6 ENTEROME SA Exhibit 128: ENTEROME SA - Overview Exhibit 129: ENTEROME SA - Product / Service Exhibit 130: ENTEROME SA - Key offerings 12.7 Evelo Biosciences Inc. Exhibit 131: Evelo Biosciences Inc. - Overview Exhibit 132: Evelo Biosciences Inc. - Product / Service Exhibit 133: Evelo Biosciences Inc. - Key offerings 12.8 Evogene Ltd. Exhibit 134: Evogene Ltd. - Overview Exhibit 135: Evogene Ltd. - Business segments Exhibit 136: Evogene Ltd. - Key offerings Exhibit 137: Evogene Ltd. - Segment focus 12.9 Ferring BV Exhibit 138: Ferring BV - Overview Exhibit 139: Ferring BV - Product / Service Exhibit 140: Ferring BV - Key offerings 12.10 Finch Therapeutics Group Inc. Exhibit 141: Finch Therapeutics Group Inc. - Overview Exhibit 142: Finch Therapeutics Group Inc. - Product / Service Exhibit 143: Finch Therapeutics Group Inc. - Key offerings 12.11 Johnson and Johnson Services Inc. Exhibit 144: Johnson and Johnson Services Inc. - Overview Exhibit 145: Johnson and Johnson Services Inc. - Business segments Exhibit 146: Johnson and Johnson Services Inc. - Key news Exhibit 147: Johnson and Johnson Services Inc. - Key offerings Exhibit 148: Johnson and Johnson Services Inc. - Segment focus 12.12 OptiBiotix Health Plc Exhibit 149: OptiBiotix Health Plc - Overview Exhibit 150: OptiBiotix Health Plc - Product / Service Exhibit 151: OptiBiotix Health Plc - Key offerings 12.13 PureTech Health Plc Exhibit 152: PureTech Health Plc - Overview Exhibit 153: PureTech Health Plc - Business segments Exhibit 154: PureTech Health Plc - Key offerings Exhibit 155: PureTech Health Plc - Segment focus 12.14 Second Genome Therapeutics Exhibit 156: Second Genome Therapeutics - Overview Exhibit 157: Second Genome Therapeutics - Product / Service Exhibit 158: Second Genome Therapeutics - Key offerings 12.15 Seres Therapeutics Inc. Exhibit 159: Seres Therapeutics Inc. - Overview Exhibit 160: Seres Therapeutics Inc. - Product / Service Exhibit 161: Seres Therapeutics Inc. - Key offerings 12.16 Synlogic Inc. Exhibit 162: Synlogic Inc. - Overview Exhibit 163: Synlogic Inc. - Product / Service Exhibit 164: Synlogic Inc. - Key offerings 12.17 Takeda Pharmaceutical Co. Ltd. Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 169: Inclusions checklist Exhibit 170: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 171: Currency conversion rates for US$ 13.4 Research methodology Exhibit 172: Research methodology Exhibit 173: Validation techniques employed for market sizing Exhibit 174: Information sources 13.5 List of abbreviations Exhibit 175: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio